Sanofi (SNY) Given Consensus Recommendation of “Hold” by Analysts
Shares of Sanofi (NYSE:SNY) have been given a consensus rating of “Hold” by the seventeen ratings firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $54.00.
Several equities research analysts have commented on the stock. BidaskClub cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Argus boosted their price target on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research report on Friday, June 2nd. Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/15/sanofi-sny-given-consensus-recommendation-of-hold-by-analysts.html.
Shares of Sanofi (NYSE:SNY) traded up 0.21% during midday trading on Tuesday, reaching $47.83. 440,287 shares of the company were exchanged. The firm’s 50 day moving average is $47.89 and its 200-day moving average is $46.32. The company has a market capitalization of $120.13 billion, a PE ratio of 11.30 and a beta of 0.88. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post $3.26 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Harbour Capital Advisors LLC bought a new position in shares of Sanofi during the first quarter worth $113,000. Parallel Advisors LLC boosted its position in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after buying an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC boosted its position in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after buying an additional 776 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in shares of Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after buying an additional 2,098 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares in the last quarter. 9.90% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.